A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Trial Profile

A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2016

At a glance

  • Drugs HMPL 004 (Primary) ; Mesalazine
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms NATRUL-3
  • Sponsors Hutchison MediPharma; Nutrition Science Partners
  • Most Recent Events

    • 04 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 02 Nov 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-002116-27).
    • 23 Oct 2013 New source identified and integrated (Oregon Health and Science University; IRB00009839).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top